Virbac SA (VIRP) - Total Liabilities
Based on the latest financial reports, Virbac SA (VIRP) has total liabilities worth €750.28 Million EUR (≈ $877.16 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Virbac SA (VIRP) cash flow conversion to assess how effectively this company generates cash.
Virbac SA - Total Liabilities Trend (2002–2024)
This chart illustrates how Virbac SA's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Virbac SA to evaluate the company's liquid asset resilience ratio.
Virbac SA Competitors by Total Liabilities
The table below lists competitors of Virbac SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Genscript Biotech Corporation
F:G51
|
Germany | €1.01 Billion |
|
Standex International Corporation
NYSE:SXI
|
USA | $809.75 Million |
|
Chengdu Xingrong Investment Co Ltd
SHE:000598
|
China | CN¥28.47 Billion |
|
AIR CHINA LTD H ADR/20
F:AD2B
|
Germany | €303.82 Billion |
|
Tikehau Capital
PA:TKO
|
France | €2.23 Billion |
|
Twist Bioscience Corp
NASDAQ:TWST
|
USA | $181.99 Million |
|
Upstart Holdings Inc
NASDAQ:UPST
|
USA | $2.18 Billion |
|
OPENLANE, Inc.
NYSE:OPLN
|
USA | $2.78 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Virbac SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Virbac SA market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Virbac SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Virbac SA (2002–2024)
The table below shows the annual total liabilities of Virbac SA from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €805.12 Million ≈ $941.27 Million |
+47.51% |
| 2023-12-31 | €545.81 Million ≈ $638.11 Million |
+4.73% |
| 2022-12-31 | €521.17 Million ≈ $609.30 Million |
+4.48% |
| 2021-12-31 | €498.84 Million ≈ $583.19 Million |
+9.81% |
| 2020-12-31 | €454.28 Million ≈ $531.11 Million |
-41.11% |
| 2019-12-31 | €771.38 Million ≈ $901.82 Million |
-0.71% |
| 2018-12-31 | €776.93 Million ≈ $908.32 Million |
-2.70% |
| 2017-12-31 | €798.49 Million ≈ $933.52 Million |
-10.92% |
| 2016-12-31 | €896.37 Million ≈ $1.05 Billion |
-5.47% |
| 2015-12-31 | €948.26 Million ≈ $1.11 Billion |
+12.40% |
| 2014-12-31 | €843.65 Million ≈ $986.32 Million |
+75.08% |
| 2013-12-31 | €481.86 Million ≈ $563.34 Million |
+12.25% |
| 2012-12-31 | €429.28 Million ≈ $501.88 Million |
+56.23% |
| 2011-12-31 | €274.77 Million ≈ $321.23 Million |
+18.74% |
| 2010-12-31 | €231.40 Million ≈ $270.53 Million |
+16.71% |
| 2009-12-31 | €198.27 Million ≈ $231.80 Million |
-6.32% |
| 2008-12-31 | €211.64 Million ≈ $247.43 Million |
+10.03% |
| 2007-12-31 | €192.35 Million ≈ $224.88 Million |
-10.09% |
| 2006-12-31 | €213.94 Million ≈ $250.11 Million |
+38.80% |
| 2005-12-31 | €154.14 Million ≈ $180.20 Million |
-5.42% |
| 2004-12-31 | €162.96 Million ≈ $190.52 Million |
+4.31% |
| 2003-12-31 | €156.23 Million ≈ $182.65 Million |
+16.39% |
| 2002-12-31 | €134.22 Million ≈ $156.92 Million |
-- |
About Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more